Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LUCY Innovative Eyewear	$2.20 +10.0%	$2.24	$1.57 ▼ $11.16	$10.07M	3.21	1.28 million shs	313,458 shs
MLSS Milestone Scientific	$0.58 -4.3%	$0.69	$0.38 ▼ $1.39	$45.20M	0.8	217,269 shs	160,383 shs
PSTV Plus Therapeutics	$0.54 -5.6%	$0.41	$0.16 ▼ $2.31	$32.80M	0.67	19.86 million shs	15.42 million shs
PYPD PolyPid	$3.43 -1.7%	$3.49	$2.30 ▼ $3.93	$54.54M	1.4	218,873 shs	37,477 shs

10 Stocks Set to Soar in Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LUCY Innovative Eyewear	+1.52%	+2.04%	-6.98%	-28.32%	-50.98%
MLSS Milestone Scientific	-3.54%	+11.46%	-7.40%	-35.28%	-40.99%
PSTV Plus Therapeutics	-21.40%	-24.42%	+70.80%	+13.38%	-61.45%
PYPD PolyPid	+2.05%	+7.06%	+2.95%	+22.46%	-0.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LUCY Innovative Eyewear	0.8202 of 5 stars	0.0	4.0	2.8	0.0	0.6
MLSS Milestone Scientific	2.0453 of 5 stars	3.5	3.0	0.6	2.5	0.0
PSTV Plus Therapeutics	2.7995 of 5 stars	3.3	5.0	3.1	0.0	0.6
PYPD PolyPid	3.0059 of 5 stars	3.6	5.0	2.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LUCY Innovative Eyewear	0.00	N/A	N/A	N/A
MLSS Milestone Scientific	3.00	Buy	$1.25	117.01% Upside
PSTV Plus Therapeutics	2.50	Moderate Buy	$10.83	1,898.03% Upside
PYPD PolyPid	3.17	Buy	$12.40	261.52% Upside

Current Analyst Ratings Breakdown

Latest LUCY, PSTV, PYPD, and MLSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	PYPD PolyPid	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $13.00
8/14/2025	PYPD PolyPid	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/13/2025	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/27/2025	PSTV Plus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.50 ➝ $3.00
6/25/2025	PSTV Plus Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$9.00
6/18/2025	PYPD PolyPid	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$12.00 ➝ $9.00
6/17/2025	PYPD PolyPid	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$16.00 ➝ $14.00
6/9/2025	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $13.00
6/5/2025	PSTV Plus Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $20.50
6/5/2025	PYPD PolyPid	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
6/2/2025	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$11.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LUCY Innovative Eyewear	$1.71M	5.89	N/A	N/A	$3.72 per share	0.59
MLSS Milestone Scientific	$8.61M	5.25	N/A	N/A	$0.11 per share	5.24
PSTV Plus Therapeutics	$5.82M	5.64	N/A	N/A	($1.52) per share	-0.36
PYPD PolyPid	N/A	N/A	N/A	N/A	$0.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LUCY Innovative Eyewear	-$7.77M	-$3.99	N/A	∞	N/A	-443.18%	-86.90%	-81.36%	8/18/2025 (Estimated)
MLSS Milestone Scientific	-$6.93M	-$0.07	N/A	∞	N/A	-52.01%	-60.26%	-40.23%	N/A
PSTV Plus Therapeutics	-$12.98M	-$2.94	N/A	N/A	N/A	-520.90%	N/A	-202.73%	N/A
PYPD PolyPid	-$29.02M	-$4.30	N/A	∞	N/A	N/A	-1,069.37%	-151.85%	N/A

Latest LUCY, PSTV, PYPD, and MLSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	PYPD PolyPid	-$0.53	-$0.78	-$0.25	-$0.78	N/A	N/A
5/30/2025	Q1 2025	PSTV Plus Therapeutics	-$0.17	-$0.56	-$0.39	-$1.19	$1.11 million	$1.06 million
5/14/2025	Q1 2025	PYPD PolyPid	-$0.80	-$0.70	+$0.10	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LUCY Innovative Eyewear	N/A	N/A	N/A	N/A	N/A
MLSS Milestone Scientific	N/A	N/A	N/A	N/A	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	N/A
PYPD PolyPid	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LUCY Innovative Eyewear	N/A	16.40	13.02
MLSS Milestone Scientific	N/A	2.85	1.86
PSTV Plus Therapeutics	N/A	1.03	1.03
PYPD PolyPid	4.43	0.71	0.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LUCY Innovative Eyewear	0.96%
MLSS Milestone Scientific	5.79%
PSTV Plus Therapeutics	3.28%
PYPD PolyPid	26.47%

Insider Ownership

Company	Insider Ownership
LUCY Innovative Eyewear	1.66%
MLSS Milestone Scientific	24.75%
PSTV Plus Therapeutics	0.79%
PYPD PolyPid	24.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LUCY Innovative Eyewear	9	4.58 million	4.50 million	Not Optionable
MLSS Milestone Scientific	30	78.48 million	58.61 million	Optionable
PSTV Plus Therapeutics	20	60.49 million	60.01 million	Not Optionable
PYPD PolyPid	80	15.90 million	11.97 million	No Data

LUCY, PSTV, PYPD, and MLSS Headlines

Recent News About These Companies

PolyPid Reports Strong Phase 3 Results and Financial Update

August 14 at 10:27 AM | msn.com

PolyPid Ltd. (NASDAQ:PYPD) Q2 2025 Earnings Call Transcript

August 14 at 10:27 AM | msn.com

PolyPid Ltd (PYPD) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses

August 14 at 10:27 AM | finance.yahoo.com

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

August 13 at 5:04 PM | seekingalpha.com

PolyPid sees cash runway ‘well into’ 2026

August 13 at 2:01 PM | msn.com

PolyPid Reports Positive Phase 3 Results and Strengthens Leadership

August 13 at 8:17 AM | tipranks.com

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 13 at 7:30 AM | globenewswire.com

PolyPid Ltd.: PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

August 12 at 5:57 PM | finanznachrichten.de

PolyPid appoints Tweezer-Zaks as Chief Medical Officer

August 12 at 5:57 PM | msn.com

PolyPid Appoints New Chief Medical Officer Amid Strategic Advancements

August 12 at 5:57 PM | msn.com

PolyPid Ltd. Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

August 12 at 9:00 AM | quiverquant.comQ

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

August 12 at 8:00 AM | globenewswire.com

PolyPid Ltd. (NASDAQ:PYPD) Given Average Rating of "Buy" by Brokerages

August 6, 2025 | americanbankingnews.com

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

July 30, 2025 | globenewswire.com

PYPD: Positive Topline Data From D-PLEX₁₀₀ Trial Contributes to Multiple Subsequent Benefits

July 16, 2025 | finance.yahoo.com

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

July 15, 2025 | finance.yahoo.com

PolyPid Launches Long-Acting GLP-1 Delivery Platform for Diabetes Market

July 15, 2025 | tipranks.com

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

July 15, 2025 | globenewswire.com

PolyPid Ltd. (PYPD) Latest Stock News & Headlines - Yahoo Finance

June 26, 2025 | finance.yahoo.com

PolyPid Secures $26.7 Million in Additional Funding to Extend Runway Ahead of D-PLEX₁₀₀ FDA Approval

June 18, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCY, PSTV, PYPD, and MLSS Company Descriptions

Innovative Eyewear NASDAQ:LUCY

$2.20 +0.20 (+10.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.15 -0.05 (-2.27%)

As of 04:18 PM Eastern

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.

Milestone Scientific NYSE:MLSS

$0.58 -0.03 (-4.30%)

Closing price 03:57 PM Eastern

Extended Trading

$0.58 0.00 (0.00%)

As of 04:13 PM Eastern

Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.

Plus Therapeutics NASDAQ:PSTV

$0.54 -0.03 (-5.61%)

Closing price 04:00 PM Eastern

Extended Trading

$0.56 +0.02 (+4.02%)

As of 04:19 PM Eastern

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

PolyPid NASDAQ:PYPD

$3.43 -0.06 (-1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$3.41 -0.02 (-0.58%)

As of 04:10 PM Eastern

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time